Category:

Are Economic Excesses Creating Investment Opportunity

Posted on by Admin 



Image Credit: Monstera (Pexels)


Tilt Confidently – A Perspective on Financial Markets and the Economy

 

Tilt Confidently

Economic excesses often create potential investment opportunities. When a key economic factor reaches a ridiculous level, it frequently proves profitable to expect a reversal: Recall the 10-year bond yield at 0.5% in mid-2020 (those who tilted investment bets toward rising-yield beneficiaries have since profited)—or the early-1981 extreme of 16%? Another example was 1995, when the U.S. dollar spiked to levels never seen before—nor since. In the 1990s, the labor participation rate peaked near 68% after having never risen above 60% prior to 1970. And, in the mid-1990s, following a decline of nearly 20% from its 1973 post-war high, the real-wage rate finally bottomed.

Although short-term timing on any economic trend is always a challenge, when something gets severely out of bounds, the favored odds are that it is apt to soon adjust. Today, there are several matters that could be considered remarkably out of the norm, including economic policies, inflation, various commodity prices, and geopolitical turmoil. However, in our view, the greatest economic extreme, at this time, is “confidence.”

 

Extreme Main-Street Pessimism?

Chart 1 shows a measure of U.S. consumer confidence from the 1950s to date. At present, confidence is lower than 98.5% of the time since 1952! Obviously, pessimism is at an extreme—there have been only a handful of readings as low as today. But what makes this extraordinarily uncommon is, for the last two years, confidence has plummeted while stocks have been in a strong bull market driven by a robust economic recovery. Yes, inflation is currently very high, and there is a war in Ukraine. All the same, inflation was even higher, for longer, in the 1970s when the Vietnam War was ongoing, and, yet, outside of recessions, consumer confidence sustained at much higher levels.

Nearly every significant decay in confidence occurred when the U.S. was in a recession. While an imminent recession is always possible, the likelihood that the U.S. is now in a recession—or even headed for one this year—seems rather remote. Outside of recessions, there was only one other time that confidence was as low as it is today: After a solid recovery in confidence at the start of the 2009 expansion, there was a brief confidence breakdown in mid-2011. Then, renewed fears that the expansion would fail is probably why confidence again declined. Those fears, however, proved unfounded; confidence quickly revived and embarked on a multi-year advance until the 2020 pandemic.

Is confidence about the contemporary expansion following a similar path? It bounced from about 70 to 90 during the first year of this recovery, but since last April, it has again collapsed (like in 2011). Despite strong economic growth and the S&P 500 within 5% of its all-time high, Main Street confidence remains depressed due to a combination of Federal Reserve and interest-rate fears, the highest inflation rate in decades, and Putin’s war.

In our view, even if some or all of these fears continue to fester, confidence will not likely fall much further. Indeed, it would truly be “extreme” if it did. Rather, some of the current nightmares facing the recovery will probably turn out better than feared, causing Main Street sentiment to soon lift, as it did after its 2011 break- down.

According to a Bloomberg survey of private-sector economists, the consensus for U.S. real-GDP growth in 2022 is a robust 3.5%. With Main Street characterized by excessive pessimism and solid real growth, in our view, an opportunity exists for investors to exploit the likelihood that confidence is poised to rise.

Portfolio Tilts For “Rising Confidence?”

Confidence as subdued as today’s is reminiscent of being in a recession that is nearing the start of a new economic expansion. Consequently, many of the investment options highlighted here are typically favored in the infancy of a new economic expansion. It is very odd for conviction to be so low when starting the third year of a recovery.

Nonetheless, if confidence does perk up from today’s extraordinarily low level—whether it is the start of a new expansion or the third year of an ongoing recovery—greater enthusiasm will likely run through both the economy and the stock market in a fashion similar to how it has traditionally done in a fresh recovery.

The following charts illustrate six distinct investments whose relative performance corresponds closely with consumer confidence. Investors may want to consider some of these as possible portfolio tilts.

1. Cyclicals Need Some Confidence!

Chart 2 overlays the relative return of the S&P 500’s major cyclical sectors with the Consumer Confidence Index. At least since 2002, there has been a close relationship between cyclical stock leadership and Main Street confidence. Indeed, cyclicals led after the March 2020 bear-market bottom until May 2021, when confidence rolled over. Could cyclical stocks be nearing a “mini-replay” of 2020, driven by a renewed spike in consumer confidence?

 

2. Low Quality?

With the S&P 500 Index still trying to recover from a recent correction, and yields rising at an aggressive pace, most are advocating to boost the “quality” in portfolios. However, as illustrated in Chart 3, not only is the relative price of low-quality stocks nearly the same today as at the bottom of the 2009 bear market, but a trend of improved confidence could prompt a period of leadership for low-quality stocks.

 

3. High-Beta’s Run To Continue?

High-beta stocks have led the stock market throughout most of this bull run (Chart 4) and may continue to be superior investments should Main Street confidence finally improve. Most recently, after confidence peaked last May, high-beta has slightly underperformed but has not suffered as aggressively as other confidence-sensitive investments. Nevertheless, since at least 1990, it has paid to be overweight high-beta stocks during periods of improving confidence.

 

4. An IPO Leadership Replay?

IPOs and SPACs had a massive run earlier in this bull market, followed by an epic collapse (Chart 5). The pattern is similar to the surge and plunge of Main Street confidence. While far from a perfect relationship, since at least 2009, when confidence improved, IPOs directionally outpaced. Likewise, periods of rising pessimism on Main Street have been associated with underperforming IPOs. Many perceive the IPO run as a speculative frenzy that has now been left for dead. Is it possible, though, if confidence again turns up, IPOs could have another “curtain call” in the balance of this bull market?

 

5. Smaller Cap For A Confidence Run!

Not surprisingly, as illustrated by Chart 6, smaller-cap stocks do best when consumer confidence rises. The blue line represents the price return of micro-cap stocks relative to mega-caps. The notable periods when consumer confidence surged (2009, 2011, and 2020) were all associated with solid leadership by microcap stocks. As confidence collapsed over the last year, versus the largest stocks, micro caps have relinquished about two-thirds of their cumulative outperformance since this bull market began in March 2020. If consumer confidence is poised for another revival, it may be time to tilt away from your mega-cap winners toward smaller stocks!

 

6. Tilting Toward EM Debt?

It is not obvious why EM debt tends to outpace when U.S. consumers are confident. As shown in Chart 7, since 2008, EM debt has significantly rewarded investors whenever Main Street sentiment was improving. Currently, the price of EM debt relative to Treasuries is nearly as low as it was at the stock-market bottoms of 2009 and 2020. It is not a coincidence these were periods when consumer confidence had also declined substantially. This chart is a good reminder that if Main Street confidence does soon improve, investors may need to adjust exposure to bonds as well as stocks.

Final Comments

 

Consumer confidence is now as low—or lower— than it has been in any recession in the post-war era. Considering that economic growth looks healthy and the stock market is near record highs, today’s excessive level of Main Street pessimism is odd.

Understandably, many investments that typically do poorly as pessimism rises have been severe underperformers in the last year. Even if a recession is imminent, neither consumer confidence nor sentiment-sensitive investments are likely to do much worse because both are already priced for a recession. But should today’s economic fears prove overblown, Main Street confidence is likely headed for a substantial recovery that should boost the relative results of a number of investments, including cyclicals, low-quality, high-beta, IPOs, small caps, and EM debt.

If you, too, believe there is simply too much pessimism today, get your shopping list ready and “Tilt Confidently.”

The above was reprinted with permission from Paulsen’s Perspective an institutional newsletter published by THE LEUTHOLD GROUP.

Authored by James W Paulsen, Ph.D.  Chief Investment Strategist of The Leuthold Group, LLC. Jim is a member of the investment committee, authors market and economic commentary, and works with the Leuthold investment team in serving institutional, financial advisor, and investment professional clients.

The Leuthold Group has been producing original analysis for the institutional marketplace for nearly half a century. Driven by the research, its investment management arm is centered on tactical asset allocation and disciplined quantitative methodologies.

 

 

Stay up to date. Follow us:

 

Are Economic Excesses Creating Investment Opportunity?

Posted on by Admin 



Image Credit: Monstera (Pexels)


Tilt Confidently – A Perspective on Financial Markets and the Economy

 

Tilt Confidently

Economic excesses often create potential investment opportunities. When a key economic factor reaches a ridiculous level, it frequently proves profitable to expect a reversal: Recall the 10-year bond yield at 0.5% in mid-2020 (those who tilted investment bets toward rising-yield beneficiaries have since profited)—or the early-1981 extreme of 16%? Another example was 1995, when the U.S. dollar spiked to levels never seen before—nor since. In the 1990s, the labor participation rate peaked near 68% after having never risen above 60% prior to 1970. And, in the mid-1990s, following a decline of nearly 20% from its 1973 post-war high, the real-wage rate finally bottomed.

Although short-term timing on any economic trend is always a challenge, when something gets severely out of bounds, the favored odds are that it is apt to soon adjust. Today, there are several matters that could be considered remarkably out of the norm, including economic policies, inflation, various commodity prices, and geopolitical turmoil. However, in our view, the greatest economic extreme, at this time, is “confidence.”

 

Extreme Main-Street Pessimism?

Chart 1 shows a measure of U.S. consumer confidence from the 1950s to date. At present, confidence is lower than 98.5% of the time since 1952! Obviously, pessimism is at an extreme—there have been only a handful of readings as low as today. But what makes this extraordinarily uncommon is, for the last two years, confidence has plummeted while stocks have been in a strong bull market driven by a robust economic recovery. Yes, inflation is currently very high, and there is a war in Ukraine. All the same, inflation was even higher, for longer, in the 1970s when the Vietnam War was ongoing, and, yet, outside of recessions, consumer confidence sustained at much higher levels.

Nearly every significant decay in confidence occurred when the U.S. was in a recession. While an imminent recession is always possible, the likelihood that the U.S. is now in a recession—or even headed for one this year—seems rather remote. Outside of recessions, there was only one other time that confidence was as low as it is today: After a solid recovery in confidence at the start of the 2009 expansion, there was a brief confidence breakdown in mid-2011. Then, renewed fears that the expansion would fail is probably why confidence again declined. Those fears, however, proved unfounded; confidence quickly revived and embarked on a multi-year advance until the 2020 pandemic.

Is confidence about the contemporary expansion following a similar path? It bounced from about 70 to 90 during the first year of this recovery, but since last April, it has again collapsed (like in 2011). Despite strong economic growth and the S&P 500 within 5% of its all-time high, Main Street confidence remains depressed due to a combination of Federal Reserve and interest-rate fears, the highest inflation rate in decades, and Putin’s war.

In our view, even if some or all of these fears continue to fester, confidence will not likely fall much further. Indeed, it would truly be “extreme” if it did. Rather, some of the current nightmares facing the recovery will probably turn out better than feared, causing Main Street sentiment to soon lift, as it did after its 2011 break- down.

According to a Bloomberg survey of private-sector economists, the consensus for U.S. real-GDP growth in 2022 is a robust 3.5%. With Main Street characterized by excessive pessimism and solid real growth, in our view, an opportunity exists for investors to exploit the likelihood that confidence is poised to rise.

Portfolio Tilts For “Rising Confidence?”

Confidence as subdued as today’s is reminiscent of being in a recession that is nearing the start of a new economic expansion. Consequently, many of the investment options highlighted here are typically favored in the infancy of a new economic expansion. It is very odd for conviction to be so low when starting the third year of a recovery.

Nonetheless, if confidence does perk up from today’s extraordinarily low level—whether it is the start of a new expansion or the third year of an ongoing recovery—greater enthusiasm will likely run through both the economy and the stock market in a fashion similar to how it has traditionally done in a fresh recovery.

The following charts illustrate six distinct investments whose relative performance corresponds closely with consumer confidence. Investors may want to consider some of these as possible portfolio tilts.

1. Cyclicals Need Some Confidence!

Chart 2 overlays the relative return of the S&P 500’s major cyclical sectors with the Consumer Confidence Index. At least since 2002, there has been a close relationship between cyclical stock leadership and Main Street confidence. Indeed, cyclicals led after the March 2020 bear-market bottom until May 2021, when confidence rolled over. Could cyclical stocks be nearing a “mini-replay” of 2020, driven by a renewed spike in consumer confidence?

 

2. Low Quality?

With the S&P 500 Index still trying to recover from a recent correction, and yields rising at an aggressive pace, most are advocating to boost the “quality” in portfolios. However, as illustrated in Chart 3, not only is the relative price of low-quality stocks nearly the same today as at the bottom of the 2009 bear market, but a trend of improved confidence could prompt a period of leadership for low-quality stocks.

 

3. High-Beta’s Run To Continue?

High-beta stocks have led the stock market throughout most of this bull run (Chart 4) and may continue to be superior investments should Main Street confidence finally improve. Most recently, after confidence peaked last May, high-beta has slightly underperformed but has not suffered as aggressively as other confidence-sensitive investments. Nevertheless, since at least 1990, it has paid to be overweight high-beta stocks during periods of improving confidence.

 

4. An IPO Leadership Replay?

IPOs and SPACs had a massive run earlier in this bull market, followed by an epic collapse (Chart 5). The pattern is similar to the surge and plunge of Main Street confidence. While far from a perfect relationship, since at least 2009, when confidence improved, IPOs directionally outpaced. Likewise, periods of rising pessimism on Main Street have been associated with underperforming IPOs. Many perceive the IPO run as a speculative frenzy that has now been left for dead. Is it possible, though, if confidence again turns up, IPOs could have another “curtain call” in the balance of this bull market?

 

5. Smaller Cap For A Confidence Run!

Not surprisingly, as illustrated by Chart 6, smaller-cap stocks do best when consumer confidence rises. The blue line represents the price return of micro-cap stocks relative to mega-caps. The notable periods when consumer confidence surged (2009, 2011, and 2020) were all associated with solid leadership by microcap stocks. As confidence collapsed over the last year, versus the largest stocks, micro caps have relinquished about two-thirds of their cumulative outperformance since this bull market began in March 2020. If consumer confidence is poised for another revival, it may be time to tilt away from your mega-cap winners toward smaller stocks!

 

6. Tilting Toward EM Debt?

It is not obvious why EM debt tends to outpace when U.S. consumers are confident. As shown in Chart 7, since 2008, EM debt has significantly rewarded investors whenever Main Street sentiment was improving. Currently, the price of EM debt relative to Treasuries is nearly as low as it was at the stock-market bottoms of 2009 and 2020. It is not a coincidence these were periods when consumer confidence had also declined substantially. This chart is a good reminder that if Main Street confidence does soon improve, investors may need to adjust exposure to bonds as well as stocks.

Final Comments

 

Consumer confidence is now as low—or lower— than it has been in any recession in the post-war era. Considering that economic growth looks healthy and the stock market is near record highs, today’s excessive level of Main Street pessimism is odd.

Understandably, many investments that typically do poorly as pessimism rises have been severe underperformers in the last year. Even if a recession is imminent, neither consumer confidence nor sentiment-sensitive investments are likely to do much worse because both are already priced for a recession. But should today’s economic fears prove overblown, Main Street confidence is likely headed for a substantial recovery that should boost the relative results of a number of investments, including cyclicals, low-quality, high-beta, IPOs, small caps, and EM debt.

If you, too, believe there is simply too much pessimism today, get your shopping list ready and “Tilt Confidently.”

The above was reprinted with permission from Paulsen’s Perspective an institutional newsletter published by THE LEUTHOLD GROUP.

Authored by James W Paulsen, Ph.D.  Chief Investment Strategist of The Leuthold Group, LLC. Jim is a member of the investment committee, authors market and economic commentary, and works with the Leuthold investment team in serving institutional, financial advisor, and investment professional clients.

The Leuthold Group has been producing original analysis for the institutional marketplace for nearly half a century. Driven by the research, its investment management arm is centered on tactical asset allocation and disciplined quantitative methodologies.

 

 

Stay up to date. Follow us:

 

Voyager News Release

Posted on by Admin

 


Voyager News Release

Research, News, and Market Data on Voyager Digital

 

Voyager Digital Ltd. (TSX: VOYG; OTCQX: VYGVF; FRA: UCD2) is at the forefront of the rapidly evolving crypto industry, and is committed to providing the best experience for its customers.

On March 29, 2022, Voyager Digital LLC, Voyager Holdings Inc., and Voyager Digital Ltd. (together “Voyager” or the “Company”) received the following orders from certain state securities divisions that are members of a multistate working group of North American Securities Administrators Association in respect of the Voyager customer accounts that permit customers to earn rewards on their crypto balances (“Voyager Earn Accounts”).  Voyager is aware of or has received cease and desist orders from the state securities divisions of Indiana, Kentucky, New Jersey and Oklahoma, and orders to show cause or similar orders from the state securities divisions of Alabama, Texas, Vermont and Washington.  These state orders generally assert that Voyager was offering and selling securities or investment contracts in the form of Voyager Earn Accounts unregistered with the applicable state.

Voyager is in ongoing communications with these state regulators to better understand the terms in their respective regulatory orders and to clarify certain statements in the orders that Voyager believes are inaccurate.  If, as, and when effective, the orders will generally prohibit Voyager from offering new Voyager Earn Accounts or accepting additional assets into existing Voyager Earn Accounts in the impacted states.  If, as, and when effective, some of these orders will permit existing Voyager Earn Account customers to continue earning rewards on existing balances until Voyager hasresolved such orders.  Three of these orders disclose civil penalties that the applicable state intends to seek upon resolution.  Voyager is seeking clarification of the terms of each of these regulatory orders, including effective dates and how proposed civil penalties in respect of alleged violations are calculated and its due process rights.  It is Voyager’s expectation that most of these state orders will provide a transition period prior to becoming effective.

Voyager is firmly convinced that its Earn Program and the Voyager Earn Accounts are not securities and intends to demonstrate its position and defend it as necessary and appropriate.  Of course, Voyager supports appropriate regulation and will do its best to demonstrate to these regulators that Voyager has complied with the law.

   
About Voyager Digital Ltd.
Publicly traded, Voyager Digital Ltd.’s (TSX: VOYG) (OTCQB: VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing, cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 100 different crypto assets using its easy-to-use mobile application. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.
 
Forward Looking Statements

Certain information in this press release, including, but not limited to, statements regarding the Company’s interpretation of the state orders received, the intent, terms and effectiveness of the state orders, the expectation of clarification of such orders from the applicable states, future changes in laws and regulations or the interpretation thereof, the Company’s success and legal strategy in response to stat orders, future legislative change, the status and operation of the Voyager Earn Accounts, future growth and performance of the business, momentum in the businesses, future adoption of digital assets, and the Company’s anticipated results may constitute forward looking information (collectively, forward-looking statements), which can be identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” (or the negatives) or other similar variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Voyager’s actual results, performance or achievements to be materially different from any of its future results, performance or achievements expressed or implied by forward-looking statements. Moreover, Voyager operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Company management to predict all risks, the interpretation or application of existing laws by regulators, nor can Voyager assess the impact of all factors on Voyager business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Voyager may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward looking statements are subject to regulatory risks, regulatory actions and claims, the risk of changes of laws or the interpretation or application thereof, the risk that the global economy, industry, or the Company’s businesses and investments do not perform as anticipated, that revenue or expenses estimates may not be met or may be materially less or more than those anticipated, that trading momentum does not continue or the demand for trading solutions declines, customer acquisition does not increase as planned, product and international expansion do not occur as planned, risks of compliance with laws and regulations that currently apply or become applicable to the business or the interpretation or application of laws and regulations by regulatory authorities, and those other risks contained in the Company’s public filings, including in its Management Discussion and Analysis and its Annual Information Form (AIF). Factors that could cause actual results of the Company and its businesses to differ materially from those described in such forward-looking statements include, but are not limited to, the ability of the Company to continue offering Voyager Earn Accounts and to offer products and services consistent with past offerings and continue to offer new and innovative products and services,  a decline in the digital asset market or general economic conditions; changes in laws or approaches to regulation or the interpretation or application thereof, regulatory investigations, enforcement actions or other regulatory action or sanction or proceedings, the failure or delay in the adoption of digital assets and the blockchain ecosystem by institutions; changes in the volatility of crypto currency, changes in demand for Bitcoin and Ethereum, changes in the status or classification of cryptocurrency assets, cybersecurity breaches, a delay or failure in developing infrastructure for the trading businesses or achieving mandates and gaining traction; failure to grow assets under management, an adverse development with respect to an issuer or party to the transaction or failure to obtain a required regulatory approval. In connection with the forward-looking statements contained in this press release, the Company has made assumptions regarding the terms and conditions of the state orders, its ability to seek clarification, its ability to continue with the Voyager Earn Accounts, it success in responding to any state orders or other regulatory enquiries, actions or claims and the applicability, interpretation and application of existing laws and regulations. Forward-looking statements, past and present performance and trends are not guarantees of future performance; accordingly, you should not put undue reliance on forward-looking statements, current or past performance, or current or past trends. Information identifying assumptions, risks, and uncertainties relating to the Company are contained in its filings with the Canadian securities regulators available at www.sedar.com. The forward-looking statements in this press release are applicable only as of the date of this release or as of the date specified in the relevant forward-looking statement and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after that date or to reflect the occurrence of unanticipated events. The Company assumes no obligation to provide operational updates, except as required by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements, unless required by law. Readers are cautioned that past performance is not indicative of future performance and current trends in the business and demand for digital assets or in the application or interpretation of laws and regulations may not continue and readers should not put undue reliance on past performance and current trends.   All figures are in U.S. dollars unless otherwise noted.

The TSX has not approved or disapproved of the information contained herein.

SOURCE Voyager Digital, Ltd.

Press Contacts

Voyager Digital, Ltd.

Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

Cypress Development Announces Results From Its Lithium Extraction Pilot Plant In Nevada

Posted on by Admin




Cypress Development Announces Results From Its Lithium Extraction Pilot Plant In Nevada

Research, News, and Market Data on Cypress Development

 

March 30, 2022 – Vancouver, Canada – Cypress Development Corp. (TSXV: CYP) (OTCQX: CYDVF) (Frankfurt: C1Z1) ( “Cypress” or “the Company”) is pleased to announce results from its Lithium Extraction Pilot Plant in Amargosa Valley, Nevada (“Pilot Plant”). The interim test results were derived from the data acquired during the 3-, 7-, and 14-day continuous operation events, which utilized claystone from the Company’s Clayton Valley Lithium Project in Clayton Valley, Nevada. Results yielded a concentration of lithium into an intermediate solution product containing 2,700 parts per million (“ppm”) lithium with insignificant impurities (“Intermediate Solution”). This is in line with expectations and similar to the data used in the Pre-Feasibility Study (“PFS”, effective date August 5, 2020, amended March 15, 2021). This information will be incorporated in the Company’s upcoming Feasibility Study currently under the direction of Wood PLC.

Highlights:

  • Concentration of lithium into an Intermediate Solution containing 2,700 ppm lithium with insignificant impurities
  • Overall extraction rates of lithium, within the washed tails, are between 83% and 85%
  • Lithium extractions from the ion exchange in the lithium recovery area indicate separation efficiencies for lithium and major cations exceed 98%
  • Sodium and potassium removal in the lithium recovery area has approached 80% with less than 0.5% lithium entrainment
  • Overall impurity removal, specifically, magnesium, calcium, iron, and aluminum all exceed 99%
  • Work continues at the Pilot Plant evaporation process stage to allow the integration of the treatment of the Intermediate Solution to produce a high-grade concentrated lithium solution ready for off-site conversion to a final lithium product

“All primary components of the Pilot Plant are operating to design. The lithium extraction and recovery areas are meeting our expectations and we are very pleased with the optimization changes completed so far, as we are now consistently producing an Intermediate Solution containing 2,700 ppm lithium with negligible impurities” stated Dr. Bill Willoughby, President, and CEO of Cypress Development. “Our team is working on our Pilot Plant’s evaporation process to allow us to take our Intermediate Solution to a high-grade concentrated lithium solution, which is essentially our final step on-site. We expect this process to be completed and be tested in the second quarter.”

Results thus far have identified preliminary extraction rates of lithium within the washed tails are between 83% and 85%. Lithium extractions from the Lionex process are 98%. Impurity removal of magnesium, calcium, iron, and aluminum are all above 99%. Sodium and potassium removal in the lithium recovery area is 80% with less than 0.5% lithium entrainment. The remaining sodium and potassium are inconsequential to the final process.

Over the coming months, the Company will continue to run tests to further optimize its Pilot Plant and enhance its process flowsheet.

Plant Update

The Pilot Plant is undergoing modifications on an ongoing basis to further improve throughput and efficiencies. These modifications include the flowsheet with the intention of simplifying the impurity removal steps prior to lithium recovery. The Company has received most of the remaining analyses of the 1,400 samples collected during continuous operating runs. These results are undergoing compilation and review with respect to flow rates and mass balances in the various areas of the Pilot Plant and will form the basis of further optimization studies. Within the lithium recovery area, the results exceed expectations, with separation efficiencies for lithium and major cations are exceeding 98% and have confirmed the successful performance, thus far, of the Chemionex’s Lionex lithium recovery and concentration (direct lithium extraction or DLE) process.

Further, changes were made to the tailings handling. Based on the process, all recovered salt (NaCl), process solution, and water is recycled back into the system. No lithium recovery effects were noted with recycled solids and solutions. Changes to the tailing dewatering system has allowed lower moisture content the final tails to less than 40% moisture. Further changes are being made to allow washing additional lithium from the final tails.

Webinar

A webinar will be held by management of Cypress Development to discuss the results from its Lithium Extraction Pilot Plant on Wednesday March 30, 2022, at 8 a.m. Pacific time / 11 a.m. Eastern time. Shareholders, analysts, investors, and media are invited to join the live webcast by registering using the link below.

Link:  https://my.6ix.com/sa-Wg6ln

After registering, you will receive a confirmation email containing details to access the webinar via conference call or webcast.

A replay of the webcast will be available within 48 hours on the Company’s Media & Articles section of the Company’s website following the conclusion of the call.

Qualified Person

Todd Fayram, MMSA-QP is the “Qualified Person” as defined by National Instrument 43-101 and has reviewed and approved the scientific and technical disclosure contained in this news release.

About Cypress Development Corp

Cypress Development Corp. is a Canadian based advanced stage lithium exploration company, focused on developing its 100%-owned Clayton Valley Lithium Project in Nevada, USA. Work completed by Cypress led to the discovery of a world-class resource of lithium-bearing claystone adjacent to the Albemarle Silver Peak mine, North America’s only lithium brine operation. Cypress is advancing its Clayton Valley Lithium Project in Nevada towards the production of high-purity lithium hydroxide suitable for battery construction.

ON BEHALF OF CYPRESS DEVELOPMENT CORP.
WILLIAM WILLOUGHBY, PhD., PE
President & Chief Executive Officer

For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851 | Toll Free: 1 800 567 8181 | Email scacos@cypressdevelopmentcorp.com
www.cypressdevelopmentcorp.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements that may be deemed to be “forward-looking statements”. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “estimates,” “projects,” “anticipates,” “believes,” “could,” “scheduled,” and other similar words. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration, and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.

QuoteMedia Announces 22% Revenue Growth for 2021

Posted on by Admin



QuoteMedia Announces 22% Revenue Growth for 2021

Research, News, and Market Data on QuoteMedia

 

PHOENIX, March 30, 2022 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, announced financial results for the fiscal year ended December 31, 2021.

QuoteMedia provides banks, brokerage firms, private equity firms, financial planners and sophisticated investors with a more economical, higher quality alternative source of stock market data and related research information. We compete with several larger legacy organizations and a modest community of other smaller companies.  QuoteMedia provides comprehensive market data services, including streaming data feeds, on-demand request-based data (XML/JSON), web content solutions (financial content for website integration) and applications such as Quotestream Professional desktop and mobile.

Highlights for fiscal 2021 include the following:

  • Annual revenue increased to $15,174,372 in 2021 from $12,402,224 in 2020, an increase of $2,772,148 (22%).
  • Net income for 2021 was $212,372 compared to a net loss of $646,324 in 2020, an improvement in profitability of $858,696.
  • Adjusted EBITDA for 2021 was $1,649,679 compared to $734,068 in 2020, an improvement of $915,611.

“This was an enormously successful year for QuoteMedia, and we are very pleased with our results,” said Robert J. Thompson, Chairman of the Board. “We experienced strong growth across virtually every success metric, including revenue growth, profitability and market share; and we also grew and improved our product lines, data coverage and infrastructure. We are even more excited about the year to come, as we expect to maintain this momentum and improve upon the results we achieved in 2022.

“2022 has started on a positive footing. QuoteMedia entered into preliminary agreements with two large multinational financial institutions to start a range of services while definitive multi-year agreements are being finalized. Based on those new contracts and our other clients currently under contract, we expect our revenue growth in fiscal 2022 to be comparable to the 22% annual revenue growth rate we achieved in 2021; and we expect to significantly improve upon the $212,372 net income figure reported in 2021.

“Additionally, because of the efforts and investments we made to improve our infrastructure, security, and business continuity management over the last year, we anticipate achieving our SOC2 Type II certification in the coming months. SOC2 certification provides independent assurance that an organization maintains a high level of information security, data integrity and business resiliency. This certification will allow QuoteMedia to make even greater gains in market share, as it is increasingly becoming a requirement for those providing services to large financial institutions.

“2021 was a very good year for QuoteMedia, and 2022 looks like it may be even better.”

QuoteMedia will host a conference call Wednesday, March 30, 2022 at 2:00 PM Eastern Time to discuss the 2021 financial results and provide a business update.

Conference Call Details:

Date: March 30, 2022

Time: 2:00 PM Eastern

Dial-in number: 866-831-8713

Conference ID: QUOTEMEDIA

An audio rebroadcast of the call will be available later at: www.quotemedia.com

About QuoteMedia

QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies. The Company licenses interactive stock research tools such as streaming real-time quotes, market research, news, charting, option chains, filings, corporate financials, insider reports, market indices, portfolio management systems, and data feeds. QuoteMedia provides industry leading market data solutions and financial services for companies such as the Nasdaq Stock Exchange, TMX Group (TSX Stock Exchange), Canadian Securities Exchange (CSE), London Stock Exchange Group, FIS, U.S. Bank, Broadridge Financial Systems, JPMorgan Chase, CI Financial, Canaccord Genuity Corp., Hilltop Securities, HD Vest, Stockhouse, Zacks Investment Research, General Electric, Boeing, Bombardier, Telus International, Business Wire, PR Newswire, FolioFN, Regal Securities, ChoiceTrade, Cetera Financial Group, Dynamic Trend, Inc., Qtrade Financial, CNW Group, IA Private Wealth, Ally Invest, Inc., Suncor, Virtual Brokers, Leede Jones Gable, Firstrade Securities, Charles Schwab, First Financial, Cirano, Equisolve, Stock-Trak, Mergent, Cision, Day Trade Dash and others. Quotestream®, QModTM and Quotestream ConnectTM are trademarks of QuoteMedia. For more information, please visit www.quotemedia.com .

Statements about QuoteMedia’s future expectations, including future revenue, earnings, and transactions, as well as all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. QuoteMedia intends that such forward-looking statements be subject to the safe harbors created thereby. These statements involve risks and uncertainties that are identified from time to time in the Company’s SEC reports and filings and are subject to change at any time. QuoteMedia’s actual results and other corporate developments could differ materially from that which has been anticipated in such statements.

Below are the specific forward-looking statements included in this press release:

  • Based on those new contracts and our other clients currently under contract, we expect our revenue growth in fiscal 2022 to be comparable to the 22% annual revenue growth rate we achieved in 2021; and we expect to significantly improve upon the $212,372 net income figure reported in 2021.
  • Additionally, because of the efforts and investments we made to improve our infrastructure, security, and business continuity management over the last year, we anticipate achieving our SOC2 Type II certification in the coming months. SOC2 certification provides independent assurance that an organization maintains a high level of information security, data integrity and business resiliency. This certification will allow QuoteMedia to make even greater gains in market share, as it is increasingly becoming a requirement for those providing services to large financial institutions.
  • 2021 was a very good year for QuoteMedia, and 2022 looks like it may be even better.

QuoteMedia Investor Relations
Brendan Hopkins
Email: investors@quotemedia.com
Call: (407) 645-5295

Note 1 on Non-GAAP Financial Measures

We believe that Adjusted EBITDA, as a non-GAAP pro forma financial measure, provides meaningful information to investors in terms of enhancing their understanding of our operating performance and results, as it allows investors to more easily compare our financial performance on a consistent basis compared to the prior year periods. This non-GAAP financial measure also corresponds with the way we expect investment analysts to evaluate and compare our results. Any non-GAAP pro forma financial measures should be considered only as supplements to, and not as substitutes for or in isolation from, or superior to, our other measures of financial information prepared in accordance with GAAP, such as net income attributable to QuoteMedia, Inc.

We define and calculate Adjusted EBITDA as net income attributable to QuoteMedia, Inc., plus: 1) depreciation and amortization, 2) stock compensation expense, 3) interest expense, 4) foreign exchange loss (or minus a foreign exchange gain), and 5) income tax expense. We disclose Adjusted EBITDA because we believe it is a useful metric by which to compare the performance of our business from period to period. We understand that measures similar to Adjusted EBITDA are broadly used by analysts, rating agencies, investors and financial institutions in assessing our performance. Accordingly, we believe that the presentation of Adjusted EBITDA provides useful information to investors. The table below provides a reconciliation of Adjusted EBITDA to net income attributable to QuoteMedia, Inc., the most directly comparable GAAP financial measure.

QuoteMedia, Inc. Adjusted EBITDA Reconciliation to Net Loss

2021 2020
Net income (loss) $ 212,372 $ (646,324 )
Depreciation and amortization 1,640,245 1,331,910
Stock-based compensation 31,876 37,872
Interest expense 2,641 4,582
Foreign exchange loss (107,382 ) 3,791
Income tax expense 3,184 2,237
PPP loan forgiveness (133,257 ) –
Adjusted EBITDA $ 1,649,679 $ 734,068

What is a Stock Split?

Posted on by Admin


Why Stocks Split and the Possible Impact to Investors

 

Reason for a Company to Split its Stock

When stocks split, it is most often a decision by the company to lower its trading price range to a level small enough to attract more investors and enhance the liquidity of trading in its shares.

Variations of Splits

A company’s board of directors may decide to split the stock by any ratio. For example, the most common is 2:1 (the stockholder receives two shares for each one they own), but 3:1, even 5:1 is not uncommon. In a 2:1 split there will be double the amount of shares trading, the price per share will approximate half of what it was before the split.

Impact to Market Cap

Market capitalization is calculated by multiplying the total number of shares outstanding by the price per share. For example, if XYZ Corp. has 10 million shares outstanding and the shares are trading at $20 Its market cap will be 200 million. If the company’s board of directors decides to split the stock 2:1 the number of shares outstanding would double to 20 million, while the share price would be roughly halved to $10.

Reasons for a Stock Split

The decision to go through the administrative expense is usually based on one or two of the following:

First, stocks traditionally traded in “round-lots” of 100 and multiples of 100. Companies often decide on a split when the stock price has reached a level where it is preventing those that the company would most likely want as owners from investing in round-lots.  

Second, the lower priced, higher number of shares outstanding can result in greater liquidity for the stock. This is because it facilitates transactions and could narrow the spread between bid and offer.

Increased liquidity helps owners large and small find buyers when they are looking to sell, and sellers when they are looking to buy. With high liquidity, a large number of shares can be traded without much impact on price levels. While this is positive for all who transact in the shares, companies that may look to repurchase their shares also don’t have as much concern about escalating the price they’re paying. Management can also exercise their ability to sell large amounts they may have acquired as part of their compensation without causing the price to plummet.

Stock Price

While a split, in theory, should have no effect on a stock’s price, it often results in renewed investor interest, which can have a positive effect. Stock splits by large heavily traded companies are often bullish for their market capitalization numbers, and positive for investors.

When You Own Shares

When a stock you own splits, shareholders of record are credited with their additional shares. For instance, in a 2:1 stock split, if you owned 100 shares that were trading at $20 just before the split, you would then own 200 shares at about $10 each. Your broker would handle this automatically, so there is nothing you need to do.

Will a Stock Split Affect My Taxes?

No. The cost basis of each share owned after the stock split will be half of what it was before the split for tax purposes.

 

Are Stock Splits Good or Bad?

Stock splits are usually done when the share price has risen so high that it might reduce trading. This means investors were driving the company valuation higher. So splits often happen in healthy growing companies. Plus, a stock that has just split may see an uptick in interest as it attracts new investors at the lower price tag per share.

 

Suggested Reading



What is Fed Tightening?

What is the Yield Curve?

 

Stay up to date. Follow us:

 

Aurania Resources (AUIAF)(ARU:CA) – Equity and Debt Financing Improves Financial Flexibility and Outlook

Posted on by Admin

Tuesday, March 29, 2022

Aurania Resources (AUIAF)(ARU:CA)
Equity and Debt Financing Improves Financial Flexibility and Outlook

As of April 24, 2020, Noble Capital Markets research on Aurania Resources is published under ticker symbols (AUIAF and ARU:CA). The price target is in USD and based on ticker symbol AUIAF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Aurania Resources Ltd. is a Canada-based junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities-Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The company also has several minor projects in Switzerland.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Equity financing. Aurania closed the first tranche of a private placement with the sale of 1,586,653 units at a price of C$0.70 per unit for gross proceeds of C$1,110,997.10. Aurania previously announced its intention to raise up to C$1,500,000 with the sale of up to 2,142,857 units which are comprised of one common share and one common share purchase warrant which may be exercised to purchase one common share at a price of C$1.25 for a period of 24 months after the close of the offering.

    Second tranche to close shortly.  A second tranche is expected to close shortly and net proceeds will be used to maintain annual mineral concessions in Ecuador and to conduct further exploration and target refinement at the Awacha porphyry copper target and the Kuri-Yawi and Kuripan epithermal gold targets …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Release – Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

Posted on by Admin



Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

Research, News, and Market Data on Ayala Pharmaceuticals

 

– Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 –

REHOVOT, Israel and WILMINGTON, Del., March 28, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Ayala or the Company) (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers today announced full-year 2021 financial results and provided a corporate update.

“2022 is off to a very promising start for Ayala, following a number of important accomplishments across our pipeline of innovative gamma-secretase inhibitors in 2021,” said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. “We are pleased with the progress of our AL102 program in desmoid tumors, having recently completed enrollment in Part A of the open label RINGSIDE study. We are encouraged by initial positive feedback received from investigators so far. We plan to announce initial interim data from Part A around mid-year 2022 and intend to move into Part B, the randomized portion of the study, immediately thereafter. We look forward to announcing additional data readouts and updates on our other clinical programs throughout 2022 including further data on AL101 in adenoid cystic carcinoma.”

2021 and Recent Business and Clinical Highlights

  • Completed enrollment of Part A of the Phase 2/3 RINGSIDE study of AL102 in desmoid tumors: 36 patients have been enrolled in Part A of the RINGSIDE study, which is evaluating the safety and tolerability of AL102, as well as tumor volume by MRI at 16 weeks. Ayala expects to report an initial interim data read-out around mid-2022, with Part B of the study commencing immediately thereafter.
  • Initiated “Window of Opportunity” study of AL101 in adenoid cystic carcinoma (ACC): The study is focused on determining the effects of AL101 for the treatment of ACC and other cancers. The goals of the study are to better understand the mechanism of AL101, determine the best treatment regime and generate data for the future development strategy. The study is being conducted in collaboration with M.D. Anderson Cancer Center and the Adenoid Cystic Carcinoma Research Foundation. 
  • Presented positive preliminary clinical data from the ongoing ACCURACY trial in ACC: Updated interim data from the 6mg cohort of the Phase 2 ACCURACY study of AL101 in recurrent/metastatic adenoid cystic carcinoma (R/M ACC) were presented at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating partial responses in three subjects (9%) and stable disease in 20 subjects (61%). At ESMO, the Company also presented preclinical proof of concept data on AL101 in combination with approved cancer therapies in patient-derived ACC tumor models
  • Initiated Phase 1 trial of AL102 in combination with Novartis’ B-cell maturation antigen (BCMA) targeting agent WVT078 in relapsed/refractory multiple myeloma (MM): inhibition of gamma-secretase with AL102 prevents the cleavage and shedding of BCMA, which is ubiquitously expressed on MM cells. Preclinical data have demonstrated that treatment with AL102 increases the expression of membrane-bound BCMA on the surface of MM cells and could enhance the activity of WVT078. Ongoing patient enrollment continues as planned.
  • AL101 in Notch-activated triple negative breast cancer: The Company has elected to discontinue the Phase 2 TENACITY study as part of its efforts to focus its resources on the more advanced programs and studies including the RINGSIDE study in desmoid tumors and the ACCURACY study for ACC.

Upcoming Milestones

  • Initial interim data from the pivotal Phase 2/3 RINGSIDE trial in desmoid tumors (Mid-2022): Ayala expects to report an initial interim data read-out from Part A of the Phase 2/3 RINGSIDE trial of AL102 in desmoid tumors around mid-2022. Part B of the study will be a double-blind placebo-controlled study and will start immediately after dose selection from Part A.
  • Additional data from the Phase 2 ACCURACY trial of AL101 in ACC: The ongoing ACCURACY trial is an open-label, single-arm Phase 2 clinical trial evaluating AL101 as monotherapy for the treatment of R/M ACC patients with Notch-activated mutations. The first cohort of the trial included 45 subjects dosed at 4 mg of AL101 IV once weekly. Final data from the 4 mg cohort and additional data from the 6 mg cohort,which includes 42 subjects are expected to be reported in the second half of 2022.
  • Initiate Phase 2 Clinical Trial Evaluating AL102 in T-cell Acute Lymphoblastic Leukemia (T-ALL): Ayala plans to begin a Phase 2 clinical trial evaluating AL101 in R/R T-ALL in the second half of 2022.

Full Year 2021 Financial Results

Cash Position: Cash and cash equivalents were $37.3 million as of December 31, 2021, as compared to $42.4 million as of December 31, 2020.

Collaboration Revenue: Collaboration revenue was $3.5 million for the full year of 2021, as compared to $3.7 million for the full year of 2020.

R&D Expenses: Research and development expenses were $29.9 million for the full year 2021, compared to $22.4 million in 2020. The increase was primarily driven by additional costs in connection with the initiation and advancement of the Phase 2/3 RINGSIDE pivotal study for desmoid tumors.

G&A Expenses: General and administrative expenses were $9.3 million as of December 31, 2021, compared to $7.4 million as of December 31, 2020. The increase was primarily due to higher expenses in connection with our operations as a public company, including director and officer insurance, increased headcount, and stock-based compensation.

Net Loss: Net loss was $40.3 million for the full year 2021, resulting in basic and diluted net loss per share of ($2.80). This compares with a net loss was $30.1 million for the full year of 2020, equivalent to basic and diluted net loss per share of ($3.06).

For further details on the Company’s financial results, refer to our Annual Report on Form 10-K, for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (SEC) on March 28, 2022.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers,. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently in a pivotal Phase 2/3 clinical trial for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements relating to our development of AL101 and AL102, the promise and potential impact of our preclinical or clinical trial data, the timing of and plans to initiate additional clinical trials of AL101 and AL102, the timing and results of any clinical trials or readouts, the sufficiency of cash to fund operations, and the anticipated impact of COVID-19, on our business. These forward-looking statements are based on management’s current expectations. The words ”may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability; we will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of AL101 and AL102; we have identified conditions and events that raise substantial doubt about our ability to continue as a going concern; we have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability; we are heavily dependent on the success of AL101 and AL102, our most advanced product candidates, which are still under clinical development, and if either AL101 or AL102 does not receive regulatory approval or is not successfully commercialized, our business may be harmed; due to our limited resources and access to capital, we must prioritize development of certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business; the outbreak of COVID-19, may adversely affect our business, including our clinical trials; our ability to use our net operating loss carry forwards to offset future taxable income may be subject to certain limitations; our product candidates are designed for patients with genetically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop product candidates is novel and may never lead to marketable products; we were not involved in the early development of our lead product candidates; therefore, we are dependent on third parties having accurately generated, collected and interpreted data from certain preclinical studies and clinical trials for our product candidates; enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control; if we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business will be harmed; our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales; the market opportunities for AL101 and AL102, if approved, may be smaller than we anticipate; we may not be successful in developing, or collaborating with others to develop, diagnostic tests to identify patients with Notch-activating mutations; we have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates; even if we obtain FDA approval for our product candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential; we have been granted Orphan Drug Designation for AL101 for the treatment of ACC and may seek Orphan Drug Designation for other indications or product candidates, and we may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for our other product candidates; although we have received Fast Track designation for AL101, and may seek Fast Track designation for our other product candidates, such designations may not actually lead to a faster development timeline, regulatory review or approval process; we face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively; we are dependent on a small number of suppliers for some of the materials used to manufacture our product candidates, and on one company for the manufacture of the active pharmaceutical ingredient for each of our product candidates; our existing collaboration with Novartis is, and any future collaborations will be, important to our business. If we are unable to maintain our existing collaboration or enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected; enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set; if we are unable to obtain, maintain, protect and enforce patent and other intellectual property protection for our technology and products or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our markets; we may engage in acquisitions or in-licensing transactions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources; and risks related to our operations in Israel could materially adversely impact our business, financial condition and results of operations.

These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022 and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

AYALA PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share and per share data)

    December 31,     December 31,  
    2021     2020  
Assets            
Current Assets:            
Cash and Cash Equivalents   $ 36,982     $ 42,025  
Short-Term Restricted Bank Deposits     122       90  
Trade Receivables     –       681  
Prepaid Expenses and Other Current Assets     2,636       1,444  
Total Current Assets     39,740       44,240  
Long-Term Assets:                
Other Assets     267       305  
Property and Equipment, Net     1,120       1,283  
Total Long-Term Assets     1,387       1,588  
Total Assets   $ 41,127     $ 45,828  
Liabilities and Stockholders’ Equity:                
Current Liabilities:                
Trade Payables   $ 3,214     $ 3,726  
Other Accounts Payables     3,258       3,151  
Total Current Liabilities     6,472       6,877  
Long-Term Liabilities:                
Long-Term Rent Liability     497       553  
Total Long-Term Liabilities   $ 497     $ 553  
Stockholders’ Equity:                
Common Stock of $0.01 par value per share; 200,000,000 shares authorized at December 31, 2021 and 2020; 14,080,383 and 12,824,463 shares issued at December 31, 2021 and 2020, respectively; 13,956,035 and 12,728,446 shares outstanding at December 31, 2021 and 2020, Respectively.   $ 139     $ 128  
Additional Paid-in Capital     145,160       109,157  
Accumulated Deficit     (111,141 )     (70,887 )
Total Stockholders’ Equity     34,158       38,398  
Total Liabilities and Stockholders’ Equity   $ 41,127     $ 45,828  
                 

AYALA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except shares and per shares data)

    Year ended     Year ended  
    December 31,     December 31,  
    2021     2020  
Revenue from License Agreement   $ 3,506     $ 3,708  
Cost of Revenue     (3,506 )     (3,708 )
Gross Profit     —       —  
Research and Development   $ 29,941     $ 22,406  
General and Administrative     9,277       7,371  
Operating Loss     (39,218 )     (29,777 )
Financial income (expenses), net     (260 )     56  
Loss before taxes on income     (39,478 )     (29,721 )
Taxes on Income     (776 )     (425 )
Net Loss   $ (40,254 )   $ (30,146 )
Net Loss per Share attributable to Common Stockholders, Basic and Diluted   $ (2.80 )   $ (3.06 )
Weighted Average Shares Used to Compute Net Loss per Share, Basic and Diluted     14,398,905       9,860,610  
                 

Release – Flotek Announces Earnings Schedule For 2021 Results

Posted on by Admin



Flotek Announces Earnings Schedule For 2021 Results

Research, News, and Market Data on Flotek Industries

 

HOUSTON, March 28, 2022 – Flotek Industries, Inc. (“Flotek” or the “Company”) (NYSE: FTK) schedule for releasing its results for the twelve months ended December 31, 2021.

In a press release to be issued after market close on Wednesday, March 30, 2022, Flotek will release its full year 2021 financial and operating results for the twelve months ended December 31, 2021. The Company will host its earnings conference call on Thursday, March 31, 2022 at 9:00 a.m. CT (10:00 a.m. ET).

To participate in the call, participants should access the webcast on www.flotekind.com under the Investor Relations section or dial 1-844-835-9986 approximately five minutes prior to the start of the call. Following the conclusion of the conference call, a recording of the call will be available on the Company’s website.

About Flotek Industries, Inc.

Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people. A technology driven, specialty green chemistry and data company, Flotek helps customers across industrial, commercial, and consumer markets improve their Environmental, Social, and Governance performance. Flotek’s Chemistry Technologies segment develops, manufactures, packages, distributes, delivers, and markets high-quality cleaning, disinfecting and sanitizing products for commercial, governmental and personal consumer use. Additionally, Flotek empowers the energy industry to maximize the value of their hydrocarbon streams and improve return on invested capital through its real-time data platforms and green chemistry technologies. Flotek serves downstream, midstream, and upstream customers, both domestic and international. Flotek is a publicly traded company headquartered in Houston, Texas, and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK.” For additional information, please visit www.flotekind.com.

Forward -Looking Statements

Certain statements set forth in this press release constitute forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934) regarding Flotek Industries, Inc.’s business, financial condition, results of operations and prospects. Words such as will, continue, expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this press release. Although forward-looking statements in this press release reflect the good faith judgment of management, such statements can only be based on facts and factors currently known to management. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Further information about the risks and uncertainties that may impact the company are set forth in the Company’s most recent filing with the Securities and Exchange Commission on Form 10-K (including, without limitation, in the “Risk Factors” section thereof), and in the Company’s other SEC filings and publicly available documents. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect, any event or circumstance that may arise after the date of this press release.

Inquiries, contact:

Investor Relations

E: ir@flotekind.com

P: (713) 726-5322

Release – Comstock Announces Full Year 2021 Results

Posted on by Admin



Comstock Announces Full Year 2021 Results

Research, News, and Market Data on Comstock Mining

 

Unveils Bioleum™ Breakthrough; A Carbon Neutral Crude Oil Capable of Replacing Fossil Crude

VIRGINIA CITY, NEVADA, MARCH 29, 2022 – Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced its 2021 results, summary of transactions completed in 2021, and our new business outlook.  

Selected Strategic Highlights

  • Approved a new strategy with a mission of enabling systemic decarbonization and a vision of a net zero carbon world.
  • Acquired Comstock Innovations, formerly Plain Sight Innovations, with a portfolio of intellectual property that contributes to global decarbonization by efficiently converting massive supplies of unused and under-utilized woody-biomass resources into cellulosic ethanol, renewable diesel, sustainable aviation fuel, and other drop-in fuels. 
  • Acquired LINICO Corporation and a developing portfolio of technologies that contribute to global decarbonization by efficiently converting a diverse array of lithium-ion batteries (“LIBs”) into electrification products, including lithium, graphite, nickel, cobalt, copper, and cathode active materials (“CAMs”). 
  • Acquired Comstock Engineering, formerly Renewable Process Solutions, whose principals built twenty six biofuel refineries in the last fifteen years and managed multiple industrial-scale projects from construction to commissioning.
  • Established and integrated new leadership, including Kevin Kreisler, President and Chief Financial Officer, William McCarthy, Chief Operating Officer, David Winsness, Chief Technology Officer, and Rahul Bobbili, Chief Engineer.
  • Advanced Cellulosic Technology.  Our cellulosic technologies can convert woody biomass into renewable fuels at extraordinary yields, including cellulosic ethanol and Bioleum™ – a remarkable new form of carbon neutral crude oil capable of replacing fossil crude for use in producing renewable diesel, aviation, and other drop-in fuels.
  • Advanced Electrification Technology.  Our electrification technologies crush, separate, and condition every class of lithium-ion battery (“LIB”) feedstock together with their host devices and other electrification residues for unrivaled throughput and flexibility, and then – in contrast to any known competing process, immediately extract lithium to produce unique “black mass” metal powders that are cleaner and far more concentrated than competing products.
  • Advanced Monetizing Non-Strategic Assets. Our announced transactions for certain mineral and other properties now total over $25 million, including expected 2022 proceeds from Tonogold, Sierra Springs and others.  

Selected Financial Results

  • Total assets nearly tripled to $126,954,632 during 2021, as compared to $43,123,562, at December 31, 2020. Net equity also nearly tripled to $92,970,522 during 2021, as compared to $31,779,206  at December 31, 2020.
  • Operating loss of $6,405,921 as compared to an operating loss of $5,474,261 for 2020, primarily resulting from increased administrative expense from acquisitions, increased personnel, and higher research and development costs.
  • Full year 2021 net loss of $24,583,620 and $(0.49) per share, as compared to full year 2020 net income of $14,931,970 and $0.49 per share. The results in each year were driven by non-routine transactions, including goodwill impairments, changes in fair values of derivatives, and gains on sales of non-strategic assets. 
  • Debt was $4,486,256 million on December 31, 2021, representing unsecured promissory notes.
  • Cash and equivalents were $5,912,188 on December 31, 2021.
  • Outstanding common shares were 67,707,832 at March 28, 2022, and 71,207,832 at December 31, 2021.

“Our operating results reflect our investments in technology, people, and the increased research and development focus during the year, as we integrated the transactions necessary to build the foundation for growth,” said Corrado De Gasperis, Comstock’s executive chairman and chief executive officer. “Our investments during the year are already yielding breakthrough advancements in technology, and our team is making remarkable progress.”

Enabling Systemic Decarbonization – Cellulosic Fuels

The Company previously announced its plans to build, own, and operate a fleet of advanced carbon neutral extraction and refining facilities, with the goal of generating over $16 billion in revenue on an annualized basis by 2030. The Company has now formed a renewable fuels subsidiary, Comstock Fuels, that will efficiently convert wasted, unused, widely available, and rapidly replenishable woody biomass into advanced cellulosic fuels, unlocking vast quantities of historically underutilized feedstocks. These fuels work in existing infrastructure, depots, fueling stations, vehicles, and anything that burns fossil fuels. Just one of our biorefineries can produce over 100 million gallons of biofuel per year, including over 70 million gallons of cellulosic ethanol and 30 million gallons of renewable diesel from just 1 million metric tons of woody biomass per year. 

“The scale of the financial and environmental impact that we can enable with our technologies is staggering,” continued De Gasperis. “There isn’t a technology on Earth that can absorb carbon from the atmosphere as quickly as trees, or that can offset as much fossil emissions from the 1.5 billion cars and trucks on today’s roads faster than by burning renewable fuels instead of fossil fuels.  In this context, we have struck massive untapped supplies of carbon neutral oil that are hidden in plain sight.”

Enabling Systemic Decarbonization – Electrification Products

Electrification and continued advancements in energy storage are vitally necessary to reduce reliance on fossil fuels while shifting to and increasing use of renewable fuels. LiNiCo holds the rights to a portfolio of innovative processes that efficiently crush and separate LIBs, extract lithium, nickel, cobalt, and graphite, and reuse the recovered metals to produce 99% pure CAMs. These technologies give LiNiCo and its existing 137,000 square foot battery metal recycling facility differentiating competitive advantages, including the ability to process upwards of 100,000 tons of LIBs per year into an array of new products.

According to International Energy Agency (“IEA”), there were more than 10 million electric vehicles (“EVs”) on the road in 2020, with new EV registrations increasing by 41% over 2019 and another 140% during the first quarter of 2021. Meeting the increased EV demand is estimated to require about five times more lithium carbonate equivalent (“LCE”) than the entire lithium mining industry produces today. The world is clearly focused on further accelerating electrification to reduce reliance on fossil fuels, creating and driving this extraordinary demand for lithium, as well as nickel, cobalt, and other critical electrification resources. The push to electrify is so urgent that the Biden Administration recently invoked the Defense Production Act to develop increased lithium production capabilities in the United States.

“Our technologies are meeting the realities of this demand shortfall by extracting lithium first, immediately and efficiently, thereby enabling profitability at the earliest stages of production. The combination of that capability with the breadth of our feedstock acceptance capabilities positions our LIB recycling business to contribute billions to our enterprise value just based on the existing valuations of comparable public companies,” continued De Gasperis.

The Company is currently building commercial pilot scale facilities for LIBs and is preparing to commence operations at its state-of-the-art battery metal recycling facility later this year. The Company has already made significant strides in forging new cellulosic revenue and licensing streams, and is currently finalizing definitive agreements and timeframes, which will be shared soon. The Company has also made meaningful progress towards completing the monetization of its non-strategic assets as quickly as possible, while funding its businesses and limiting management’s focus to the renewable objectives outlined above.

De Gasperis concluded: “We look forward to our next communication and seeing those of you who can attend this year’s Annual General Meeting on May 26, 2022, where we plan on presenting our business plans and near-term revenues. We are extraordinarily focused on the renewable energy businesses that most impact our stakeholders in 2022 and beyond.”

About Comstock Mining Inc.

Comstock Mining Inc. (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting massive supplies of under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in reports that we file with the Securities and Exchange Commission, including Item 1A, “Risk Factors” in our most recently-filed Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, mercury remediation and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mercury remediation, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with mercury remediation, metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, mercury remediation technology and efficacy, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

  Contact information:    
Comstock Mining Inc.
P.O. Box 1118
Virginia City, NV 89440
www.comstock.inc		 Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com		 Zach Spencer
Director of External Relations
Tel (775) 847-5272 Ext.151
questions@comstockmining.com

For Retail Investors AMCs CEO Adam Aron May Have Been the Biggest Star at the Oscars

Posted on by Admin 


Image Credit: Image Credit: Twitter: @CEOAdam


AMC Entertainment’s Plot Twist Gets Even More Interesting to Investors

 

While on his way to the Oscars Sunday afternoon, the CEO of AMC Entertainment spoke on the phone while his driver navigated the vehicle to Hollywood’s “big night.” He was being interviewed by Reuter’s about AMC’s recent purchase and plans for future acquisitions. What Mr. Aron revealed as part of the company’s evolution demonstrates a complete rethinking of the AMC’s strengths and what they can do to reward investors.

AMC is sitting on a large cash position that could benefit investors better if deployed to serve those that have believed in the company and invested in it during the pandemic – covid19 challenged the entertainment industry. They are beginning to recognize their current potential; this includes being able to shop for and make strategic acquisitions. The make-up of companies they would look to get involved with are those that could benefit from AMC’s competence in the capital markets.

On March 15, AMC surprised many by announcing a $27.9 million investment for a 22%
stake in Hycroft Mining Holding Corp (HYMC). This outlay initially met with some head-scratching as the investment in the Nevada-based gold mine didn’t naturally seem like a fit for a company operating 900 theaters. It was explained by the CEO that one of the company’s core competencies is navigating the capital markets, he evidenced this by pointing to its success after being left for dead by investors in 2020.  After just 10 trading days, AMC’s Hycroft purchase looks good. AMC bought Hycroft shares at $1.07, and it is trading this morning (March 29) at $2.44. Hycroft has since raised $139 million by selling stock to investors in a bid to strengthen its balance sheet and grow operations at its gold and silver mine.

AMC has “dry powder” of about $1.8 billion that came from selling stock during the meme stock and short squeeze frenzy.

 

 

In another Adam Aron interview held by CNBC the day after the Academy Awards, David Faber asked, “Is that the new core competence of AMC, to sort of use these meme-sters that you have to help turnaround the fortunes of a company because they’re willing to put money behind it?” “I think I have to say the answer is yes, and we proved it,” Aron responded.

This response on CNBC was not a surprise to investors that had read the Reuter’s interview where he said, “I’d like to think there will be more third-party external M&A announcements going forward…Transformational M&A is mandatory. Our shareholder base has given us capital to deploy with the clear expectation that we are… going to do exciting things with the money they entrusted to us”

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



AMC is Thinking Outside the Box Office and Diversifying

AMC Theaters Now Accepts 4 Cryptocurrencies





Is it Game-Over for Meme Stock Investors?

SPACs and Potential Sellers are Successfully Thinking Outside the Box

 

Sources

https://investor.amctheatres.com/newsroom/news-details/2022/AMC-Entertainment-Holdings-Inc.-Announces-Significant-Investment-Buying-22-of-Hycroft-Mining-Holding-Corporation/default.aspx

https://www.reuters.com/business/exclusive-amc-ceo-says-more-meme-stock-powered-deals-are-coming-2022-03-28/

https://markets.businessinsider.com/news/stocks/amc-entertainment-meme-stock-price-ceo-plans-more-deals-ahead-2022-3?utm_medium=ingest

https://www.google.com/search?q=what+is+a+transformational+acquisition

 

Stay up to date. Follow us:

 

Release – BioSig Technologies Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services

Posted on by Admin



BioSig Technologies, Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services

News and Market Data on BioSig Technologies

 

The leasing and finance program provides a non-recourse financial solution for PURE EP™ to improve purchase flexibility for U.S. hospitals

Westport, CT, March 29, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced a new partnership agreement with Summit Blue Capital for implementing a leasing and finance program for the Company’s PURE EP™ System.

The Minneapolis-based Summit Blue Capital is a leader in equipment finance and leasing. It offers tailored leasing and financing solutions for its partners and clients in industries such as healthcare, manufacturing, hospitality, technology solutions, and more. Most notably, Summit Blue Capital specializes in simplifying the financing experience and finding solutions to advance commercial roll outs in the healthcare industry.

“We believe that partnering with Summit Blue Capital will have considerable benefits to our commercial plans. We intend to take advantage of the Summit team’s expertise, flexibility, and financial solutions as a leasing partner,” said Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. “Summit Blue Capital came highly recommended by one of the largest money center U.S. financial institutions. We believe this relationship will help take friction out of the sales cycle and advance our timeline while allowing BioSig to get paid up front per installation. The team at Summit Blue Capital is expected to also help us launch a subscription-based revenue model for our software.”  

“The pathway to purchase is always of great consideration in the capital equipment forum. We anticipate that partnering with Summit Blue Capital will impact our ability to expedite PURE EP’s entrance into new electrophysiology labs across the United States,” commented Gray Fleming, Chief Commercial Officer of BioSig Technologies, Inc.

“BioSig has made significant improvements to the EP market, and they have a unique technology offering with their PURE EP,” said Adam Drill, President of Summit Blue Capital. “Summit Blue Capital is excited to partner with BioSig and execute on a strategic financing and leasing program that we believe will benefit their customer roll out and help position them as a leader in medical technology. We look forward to helping each other and building a solid foundation for the future.”

The PURE EP™ is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, 75 physicians have completed more than 2,150 patient cases with the PURE EP™ System.

Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources.

About Summit Blue Capital
Summit Blue Capital is a national commercial finance business based in Minnesota. The Company specializes in custom vendor programs and lease lines-of-credit for companies across the United States. Summit Blue is a privately owned and independently operated finance company that serves all industries. For more information, visit www.summitbluecapital.com.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119

Source: BioSig Technologies, Inc.

Release – ISG Acquires AI Platform Solution Agreemint

Posted on by Admin



ISG to Announce Third-Quarter Financial Results

Research, News, and Market Data on Information Services Group

 

Move strengthens ISG’s provider governance and risk management leadership

AI platform supports better negotiation and legal compliance of supplier contracts

Agreemint to be integrated into ISG GovernX® third-party management solution

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, said today it has acquired automated contracting solution Agreemint from its founders. Terms were not disclosed.

The AI-powered contracting platform brings important new capabilities to the market-leading ISG GovernX® vendor compliance and risk management solution and will be used by ISG to add value to future platform solutions now in development.

“Our SaaS-based GovernX platform has been one of our fastest-growing areas over the last two years, especially as large organizations seek to control costs and mitigate risk from their ever- expanding supplier ecosystems,” said Michael P. Connors, chairman and CEO of ISG. “Our acquisition of Agreemint creates the ultimate platform for enterprises to accelerate time to contract, keeping pace with their speed of technology adoption and partnership formation.”

The acquisition, Connors said, is part of ISG’s overall strategy to develop or acquire innovative SaaS-based platforms to complement its advisory business, bring more value to clients, and achieve consistent, double-digit recurring revenue growth.

Agreemint delivers automated contract authoring through a repository of legal positions to accelerate speed to contract. Its patented AI-powered smart functionality enables clients to negotiate better contracts by suggesting language proven to be legally compliant, governable and agreeable to both parties based upon analysis of previous contracting efforts. The software also anticipates language sticking points and includes a clause library that proposes pre-approved clause alternatives.

ISG has partnered with Agreemint since 2021 on solutions for several blue-chip ISG clients. Connors said the acquisition is a natural extension of that relationship and adding Agreemint software will make the ISG GovernX platform even more valuable for automating the entire contract lifecycle. GovernX has under management more than $60 billion of annual contact value, up 30 percent in the last year, across more than 10,000 client contracts, up 40 percent.

“Getting to ‘yes’ on a contract faster and more efficiently is what Agreemint is all about,” said Agreemint founder Peter Graham, who is joining ISG in an executive role. ”Agreemint’s AI-powered negotiating and contracting tools, coupled with GovernX’s extensive vendor compliance and risk management capabilities, makes GovernX the most complete solution for contract lifecycle management on the market today.”

For more information about ISG GovernX, visit this webpage. Further details about Agreemint can be found at agreemint.com.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 800 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

Source: Information Services Group, Inc.